Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeGlycoprotein D subunit vaccine's efficacy in human clinical trials
Posted by halford on 07 Jan 2012 at 22:36 GMT
Update on HSV-2 glycoprotein D (Herpevac)-based vaccine
The focus of this PLoS ONE paper was comparison of the efficacy of a novel live HSV-2 vaccine strain to a glycoprotein D-based HSV-2 vaccine, which represents a genital herpes vaccine approach that has been pursued by the pharmaceutical industry for the past ~15 years.
At the time of publication of this PLoS ONE paper, the disappointing efficacy of a glycoprotein D-based vaccine (Herpevac) in human clinical trials had been disclosed in a press release made by Glaxo Smith Klinese in Sept 2010.
The formal publication which now fully documents all of the results of the massive undertaking known as "the Herpevac clinical trial (2003 - 2007)" was published last week in the New England Journal of Medicine (http://www.nejm.org/doi/f...).
Two media articles, which summarize the published results are provided here:
Nature:
http://www.nature.com/new...
USA Today:
http://yourlife.usatoday....
- Bill Halford